Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Caredx Inc (CDNA)

Caredx Inc (CDNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,381,284
  • Shares Outstanding, K 52,627
  • Annual Sales, $ 192,190 K
  • Annual Income, $ -18,710 K
  • 60-Month Beta 0.61
  • Price/Sales 17.47
  • Price/Cash Flow N/A
  • Price/Book 8.26
Trade CDNA with:

Options Overview Details

View History
  • Implied Volatility 63.44%
  • Historical Volatility 55.89%
  • IV Percentile 70%
  • IV Rank 38.42%
  • IV High 90.14% on 03/12/21
  • IV Low 46.78% on 08/24/21
  • Put/Call Vol Ratio 0.38
  • Today's Volume 44
  • Volume Avg (30-Day) 146
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 363
  • Open Int (30-Day) 722

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.17
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.52 +5.33%
on 09/20/21
81.45 -19.15%
on 08/31/21
-7.65 (-10.41%)
since 08/20/21
3-Month
62.52 +5.33%
on 09/20/21
96.88 -32.03%
on 06/29/21
-24.40 (-27.04%)
since 06/22/21
52-Week
30.27 +117.54%
on 09/24/20
99.83 -34.04%
on 01/20/21
+32.54 (+97.69%)
since 09/22/20

Most Recent Stories

More News
CareDx Names Longtime Patient Advocate Art Torres to Board of Directors

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant...

CDNA : 65.85 (+2.49%)
3 Stocks in Cathie Wood’s ARK Genomic Revolution Fund that Wall Street Loves

The genomics industry is progressing rapidly due to its technology integration and disruptive innovations over the past few years. Renowned investor Cathie Wood has been betting big on the genomics industry,...

ADPT : 38.81 (+0.60%)
CDNA : 65.85 (+2.49%)
BLI : 23.15 (-6.46%)
CareDx Showcases Leadership in Global Transplantation at ESOT 2021

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant...

CDNA : 65.85 (+2.49%)
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save patients' lives and improve quality of life around...

MIRO : 7.00 (+6.06%)
BAX : 81.05 (-1.10%)
CDNA : 65.85 (+2.49%)
DVA : 121.11 (+1.05%)
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CDNA : 65.85 (+2.49%)
CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant...

CDNA : 65.85 (+2.49%)
CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant...

CDNA : 65.85 (+2.49%)
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CDNA : 65.85 (+2.49%)
Medexus Appoints New Chief Financial Officer

Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immediately....

MDP.VN : 7.750 (-4.91%)
MDP.TO : 3.16 (unch)
MEDXF : 2.4650 (-0.60%)
CDNA : 65.85 (+2.49%)
CareDx to Report Second Quarter 2021 Financial Results

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant...

CDNA : 65.85 (+2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of...

See More

Key Turning Points

3rd Resistance Point 69.07
2nd Resistance Point 67.68
1st Resistance Point 66.77
Last Price 65.85
1st Support Level 64.47
2nd Support Level 63.08
3rd Support Level 62.17

See More

52-Week High 99.83
Fibonacci 61.8% 73.26
Last Price 65.85
Fibonacci 50% 65.05
Fibonacci 38.2% 56.84
52-Week Low 30.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar